AMWG Action Items - Updated from 6 March 2012 meeting

DoHA tabled a paper on comparator formulary data from the 2011 PBAC meetings (March and July).

Noted that November data is not yet publicly available. The number of applications where the comparator is an F2 drug is very small. The vast majority of submissions chose, and PBAC accepted, an F1 comparator.

DoHA resent tabled paper to members on 6 March.

MA to provide qualitative analysis and identify any gaps prior to next AMWG meeting (proposed for July 2012).

DoHA to revise guidelines via the PBAC Guidelines Working Group (PGWG) – last meeting was Oct 2010. MA requested this to be revised for currency to include parallel processing and managed entry scheme.

DoHA resent tabled paper to members on 6 March.

DoHA to revise PBAC guidelines via the PGWG to include parallel processing and managed entry scheme.

DoHA and MA to develop a template for reporting – predicted versus actuals.

MA/HEWG draft framework to be endorsed by MA Board.

DoHA to provide feedback on framework to MA.

MA to provide outcomes from the Joint Medicines Policy Conference to the AMWG.

MA tabled paper on outcomes of JMPC meeting.

MA to upload outcomes from the August 2011 JMPC meeting on its website.

MA to develop paper on current activities that could progress issues raised at the JMPC, including identifying gaps and recommendations on how to address these gaps, for consideration at next AMWG meeting (proposed for July 2012).

Note: all parties have resourcing limitations so focus is on priority areas and what is already covered by existing work.

The DWG has almost completed drafting of the second PBS expenditure and growth monitoring report. Progress on this report has been slower than anticipated due to heavy workloads and resource constraints. This second report builds on the first report tabled to AMWG in August 2011.

DWG to finalise ‘Trends in and drivers of PBS expenditure’ report out of session.

DoHA to seek Ministerial approval to table report at next Pharmaceutical Industry Working Group (PIWG) meeting.

MA to respond to letter from DoHA outlining source of unpublished PBS data reported in Medicines Australia's 2012 Factbook.

MA to correct referencing on its website in relation to “unpublished PBS data from the Department of Health and Ageing”.

DoHA and MA to discuss the work of the Horizon Scanning Working Group on: a) the direction and structure of the paper; b) any particular case studies for the next report; and c) any suggestions of other ways of looking at the data.

DoHA requested the 3 – 5 year projection to continue. In relation to longer term horizon scanning, DoHA suggested a focus on areas such as fiscal impacts or where current policy or systems could create methodological challenges.

MA to do stocktake of information already available, such as the MA Factbook, and investigate how the National Health Service (NHS) undertakes horizon scanning in the UK.

MA to provide list of potential areas of horizon scanning for the long term at next AMWG meeting (proposed for July 2012).

DoHA and MA to update the PBS listing timeframes, noting they are currently being met.

(Paper was provided at May 2011 AMWG meeting).

DoHA to provide an update on post-PBAC listing timeframes at next AMWG meeting (proposed for July 2012).

The Annual Report has been drafted collaboratively and is being progressed to the Minister for tabling.

The AMWG report is one of four reports required to be tabled in Parliament.

MA provided comments end of January.

DoHA to provide final changes to MA shortly, before provision to the Minister for publication and tabling, if agreed.

DoHA and MA to provide update on MoU implementation at the next meeting, including EAPD.

Noted letter from DoHA to MA acknowledging support and outcomes of EAPD.

Noted some administrative burden by industry and DoHA in establishment of EAPD systems.

Noted legislative amendments scheduled for 1 October 2012.

Post market surveillance – the Department to provide regular updates to the AMWG in relation to the implementation of this measure.

Noted statins and anticoagulant reviews underway.

Noted NPS Medicare Insight program.

The AMWG Secretariat to prioritise the production and distribution of AMWG meeting action items.